Lenacapavir HIV Prevention: Approval and Access Strategy Updates

By Rene Pretorius

February 21, 2025

Gilead Sciences has submitted marketing authorization applications to the European Medicines Agency (EMA) for lenacapavir HIV prevention, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention. This marks a critical step in expanding prevention options.

Regulatory Submissions and Fast-Track Review for Lenacapavir

Gilead filed two applications:

  • A Marketing Authorization Application (MAA) to the European Commission for lenacapavir as PrEP.
  • An EU-Medicines for All (EU-M4all) application, enabling faster approval in low- and lower-middle-income countries by leveraging the EU’s assessment.

The EMA will conduct a parallel Accelerated Assessment, recognizing lenacapavir´s potential public health impact and therapeutic innovation.

Clinical Evidence and Safety of Lenacapavir

The submissions rely on data from Phase 3 PURPOSE 1 and PURPOSE 2 trials:

  • PURPOSE 1: Zero HIV infections among cisgender women in the lenacapavir HIV prevention group, showing 100% risk reduction compared to background HIV incidence (bHIV).
  • PURPOSE 2: Lenacapavir HIV prevention achieved a 96% risk reduction among cisgender men and gender-diverse individuals, outperforming daily oral Truvada (TDF/FTC). Only two infections occurred among 2,180 participants on lenacapavir.

Both trials confirmed lenacapavir favorable safety profile, with no significant or new safety concerns reported.

U.S. Regulatory Status and Previous Approvals

Gilead also submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) in December 2024 for PrEP. However, lenacapavir remains investigational for HIV prevention and is not yet globally approved.

Lenacapavir, marketed as Sunlenca, already has FDA approval for a different use. In 2023, the FDA approved it for adults with multi-drug resistant HIV-1, in combination with other antiretrovirals.

Expanding Global Access to Lenacapavir HIV Prevention

Gilead aims to accelerate lenacapavir’s regulatory approvals and ensure rapid availability in high-incidence regions. Its twice-yearly dosing could improve adherence compared to daily oral PrEP, offering a promising new tool in HIV prevention.

 

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...